Beta-Blocker-Induced Erythrodermic Psoriasis: A Case Report

Cureus. 2022 Oct 1;14(10):e29809. doi: 10.7759/cureus.29809. eCollection 2022 Oct.

Abstract

Beta-blockers are well-known for their wide range of therapeutic applications, particularly in patients with cardiac diseases. Physicians worldwide are aware of their potential side effects, including hypoglycemia, dizziness, slow heart rate, fatigue, and heart block. We report a case of erythrodermic psoriasis caused by beta-blockers in a 61-year-old woman with no prior history of the skin condition. The diagnosis was made based on the characteristic histopathological picture and a Naranjo score of 6. She was administered 15 mg of methotrexate weekly and received supportive care. She recovered completely within two months and exhibited no recurrence of symptoms.

Keywords: beta-blocker; beta-blocker-induced psoriasis; case report; drug-induced psoriasis; erythrodermic psoriasis; psoriasis.

Publication types

  • Case Reports